Company news

Syndax Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

December 11, 2023

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

December 10, 2023

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

December 9, 2023

Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting

December 3, 2023

Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting

November 20, 2023

Syndax Announces Participation at Stifel Healthcare Conference

November 6, 2023

Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

November 1, 2023

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting

November 1, 2023

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

November 1, 2023

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

October 25, 2023

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program

October 23, 2023

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

October 1, 2023

Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023

September 28, 2023

Syndax Announces Participation at the Citi 18th Annual BioPharma Conference

August 30, 2023

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 4, 2023

Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

August 2, 2023

Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023

July 24, 2023

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

July 23, 2023

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 7, 2023

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

April 30, 2023

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

March 29, 2023

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

March 14, 2023

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

February 27, 2023

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

February 20, 2023

Syndax Announces Participation at Upcoming Investor Conferences

February 13, 2023

Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

December 13, 2022

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

December 9, 2022

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

December 7, 2022

Syndax Announces Proposed $150 million Public Offering of Common Stock

December 5, 2022

Syndax Announces Pricing of $150 Million Public Offering of Common Stock

December 5, 2022

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

December 4, 2022

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

December 4, 2022

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

December 1, 2022

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

November 20, 2022

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

November 2, 2022

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

November 2, 2022

Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

October 26, 2022

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

August 7, 2022

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

August 1, 2022

Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer

June 12, 2022

Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

May 10, 2022

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update

May 8, 2022

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

May 1, 2022

Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update

February 28, 2022

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

February 28, 2022

Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022

February 21, 2022

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development

February 2, 2022

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

January 19, 2022

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.